Literature DB >> 35835879

Evaluation of diffuse glioma grade and proliferation activity by different diffusion-weighted-imaging models including diffusion kurtosis imaging (DKI) and mean apparent propagator (MAP) MRI.

Sheng-Hui Xie1,2, Rui Lang3, Bo Li2, He Zhao2, Peng Wang2, Jin-Long He2, Xue-Ying Ma2, Qiong Wu2, Shao-Yu Wang4, Hua-Peng Zhang4, Yang Gao2, Jian-Lin Wu5.   

Abstract

PURPOSE: To evaluate two advanced diffusion models, diffusion kurtosis imaging and the newly proposed mean apparent propagation factor-magnetic resonance imaging, in the grading of gliomas and the assessing of their proliferative activity.
METHODS: Fifty-nine patients with clinically diagnosed and pathologically proven gliomas were enrolled in this retrospective study. All patients underwent DKI and MAP-MRI scans. Manually outline the ROI of the tumour parenchyma. After delineation, the imaging parameters were extracted using only the data from within the ROI including mean diffusion kurtosis (MK), return-to-origin probability (RTOP), Q-space inverse variance (QIV) and non-Gaussian index (NG), and the differences in each parameter in the classification of glioma were compared. Receiver operating characteristic (ROC) curve analysis was used to evaluate the diagnostic performance of these parameters.
RESULTS: MK, NG, RTOP and QIV were significantly different amongst the different grades of glioma. MK, NG and RTOP had excellent diagnostic value in differentiating high-grade from low-grade glioma, with largest areas under the curve (AUCs; 0.929, 0.933 and 0.819, respectively; P < 0.01). MK and NG had the largest AUCs (0.912 and 0.904) when differentiating grade II tumours from III tumours (P < 0.01) and large AUCs (0.791 and 0.786) when differentiating grade III from grade IV tumours. Correlation analysis of tumour proliferation activity showed that MK, NG and QIV were strongly correlated with the Ki-67 LI (P < 0.001).
CONCLUSION: MK, RTOP and NG can effectively represent the microstructure of these altered tumours. Multimodal diffusion-weighted imaging is valuable for the preoperative evaluation of glioma grade and tumour proliferative activity.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  DKI; Glioma magnetic resonance imaging; Ki-67; Label index; MAP-MRI

Year:  2022        PMID: 35835879     DOI: 10.1007/s00234-022-03000-0

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.995


  23 in total

Review 1.  Physics, Techniques and Review of Neuroradiological Applications of Diffusion Kurtosis Imaging (DKI).

Authors:  M Marrale; G Collura; M Brai; N Toschi; F Midiri; G La Tona; A Lo Casto; C Gagliardo
Journal:  Clin Neuroradiol       Date:  2015-11-20       Impact factor: 3.649

2.  Diagnosis of malignant glioma: role of neuropathology.

Authors:  Daniel J Brat; Richard A Prayson; Timothy C Ryken; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2008-08-20       Impact factor: 4.130

3.  CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010.

Authors:  Quinn T Ostrom; Haley Gittleman; Paul Farah; Annie Ondracek; Yanwen Chen; Yingli Wolinsky; Nancy E Stroup; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2013-11       Impact factor: 12.300

4.  [Effect of brain edema on the recurrence pattern of malignant gliomas].

Authors:  M Hartmann; O Jansen; T Egelhof; M Forsting; F K Albert; K Sartor
Journal:  Radiologe       Date:  1998-11       Impact factor: 0.635

5.  Proliferating cell nuclear antigen and Ki-67 immunohistochemistry of oligodendrogliomas with special reference to prognosis.

Authors:  S Heegaard; H M Sommer; H Broholm; O Broendstrup
Journal:  Cancer       Date:  1995-11-15       Impact factor: 6.860

6.  IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO.

Authors:  David E Reuss; Yasin Mamatjan; Daniel Schrimpf; David Capper; Volker Hovestadt; Annekathrin Kratz; Felix Sahm; Christian Koelsche; Andrey Korshunov; Adriana Olar; Christian Hartmann; Jaap C Reijneveld; Pieter Wesseling; Andreas Unterberg; Michael Platten; Wolfgang Wick; Christel Herold-Mende; Kenneth Aldape; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2015-05-12       Impact factor: 17.088

Review 7.  The assessment of Ki-67 as a prognostic marker in neuroendocrine tumours: a systematic review and meta-analysis.

Authors:  Sebastian Richards-Taylor; Sean M Ewings; Eleanor Jaynes; Charles Tilley; Sarah G Ellis; Thomas Armstrong; Neil Pearce; Judith Cave
Journal:  J Clin Pathol       Date:  2015-12-17       Impact factor: 3.411

8.  The added value of the apparent diffusion coefficient calculation to magnetic resonance imaging in the differentiation and grading of malignant brain tumors.

Authors:  Nail Bulakbasi; Inanc Guvenc; Onder Onguru; Ersin Erdogan; Cem Tayfun; Taner Ucoz
Journal:  J Comput Assist Tomogr       Date:  2004 Nov-Dec       Impact factor: 1.826

9.  Peritumoral edema on MRI at initial diagnosis: an independent prognostic factor for glioblastoma?

Authors:  K Schoenegger; S Oberndorfer; B Wuschitz; W Struhal; J Hainfellner; D Prayer; H Heinzl; H Lahrmann; C Marosi; W Grisold
Journal:  Eur J Neurol       Date:  2009-04-14       Impact factor: 6.089

Review 10.  The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Pieter Wesseling; Daniel J Brat; Ian A Cree; Dominique Figarella-Branger; Cynthia Hawkins; H K Ng; Stefan M Pfister; Guido Reifenberger; Riccardo Soffietti; Andreas von Deimling; David W Ellison
Journal:  Neuro Oncol       Date:  2021-08-02       Impact factor: 13.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.